Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer

Targeted radiotherapy has become one of the hottest areas in oncology, driving more than $30 billion in pharma deals over the past three years. Prostate, lung, and breast cancer alone account for over $60 billion in annual drug spending, yet resistance to current therapies continues to create costly failures. Actinium Pharmaceuticals (NYSE American: ATNM) is positioned at the intersection of this trend, advancing an alpha-based radiotherapy platform designed for high-value, post-resistance settings.

A New Angle in Radiotherapy

ATNM-400's targeting of Steap-1 gives Actinium a clear opening in three of the largest solid-tumor markets: prostate, breast, and lung cancer. Steap-1 is not a niche marker - it's a cell-surface protein linked to tumor growth, metastasis, and treatment resistance. It remains expressed even after prostate cancer patients fail ARPI therapy or Pluvicto, and its expression increases in resistant breast cancer. For investors, this is the kind of biological consistency that supports multi-indication development rather than a single-asset gamble.

Prostate Cancer: Addressing a Clear Unmet Need

Metastatic castration-resistant prostate cancer (mCRPC) is dominated by ARPI drugs and PSMA-targeted radioligands, both of which face significant resistance. Up to 30% of patients don't respond to PSMA radioligand therapy, and nearly all develop resistance within a year. ATNM-400 bypasses this problem by targeting Steap-1. Preclinical data show it outperforms enzalutamide and 177Lu-PSMA-617, including in resistant models, with strong synergy when paired with enzalutamide, opening the door to frontline, combination, or sequential strategies.

Lung Cancer: A Second High-Value Entry Point

Non-small cell lung cancer (NSCLC) is another massive market where resistance limits outcomes. Osimertinib dominates first-line therapy, but resistance emerges universally, and second- and third-line agents face the same durability and toxicity challenges. ATNM-400 demonstrated superior efficacy in preclinical studies, including in osimertinib-resistant models, and shows synergy with standard EGFR therapy, positioning Actinium to partner strategically in this market rather than compete.

Breast Cancer: Expanding the Opportunity

SABCS data highlight ATNM-400's activity across HR+, HER2+, and triple-negative breast cancer (TNBC). Importantly, it retains potency in tamoxifen-resistant and trastuzumab-resistant models, addressing a high-unmet-need population where relapse rates are high and options are limited. Steap-1 expression increases in these resistant subtypes, supporting precise patient selection and scalable commercial potential. The Ac-225 payload could also reduce off-target toxicities, such as interstitial lung disease, that limit antibody drug conjugates.

A Cohesive Multi-Indication Platform

Across prostate, NSCLC, and breast cancer, ATNM-400 combines a validated target with alpha-radiation potency. Preclinical data show it outperforms or restores sensitivity to standard therapies, creating a platform radiotherapy program rather than a single-indication asset. Actinium's manufacturing expertise in Ac-225 and broad IP portfolio further strengthen the investment case.

Conclusion

ATNM-400 positions Actinium (NYSE American: ATNM) at the forefront of a multi-billion-dollar oncology market. With a differentiated mechanism, strong preclinical performance, and clear multi-indication potential, ATNM offers investors a catalyst-rich story in targeted radiotherapy. Early clinical signals could transform the company from a niche developer into a central player in next-generation alpha-based oncology.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of content related to ANTM. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=actinium-pharmaceuticals-inc-nyse-american-atnm-advances-atnm400-targeting-steap1-across-prostate-breast-and-lung-cancer]
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.